These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

689 related items for PubMed ID: 24766095

  • 1. Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches.
    Karaiskos I, Giamarellou H.
    Expert Opin Pharmacother; 2014 Jul; 15(10):1351-70. PubMed ID: 24766095
    [Abstract] [Full Text] [Related]

  • 2. Treatment of infections caused by multidrug-resistant Gram-negative bacilli: A practical approach by the Italian (SIMIT) and French (SPILF) Societies of Infectious Diseases.
    Meschiari M, Asquier-Khati A, Tiseo G, Luque-Paz D, Murri R, Boutoille D, Falcone M, Mussini C, Tattevin P, Italian Society of Infectious and Tropical Diseases (SIMIT), and the French Society of Infectious Diseases (SPILF).
    Int J Antimicrob Agents; 2024 Jul; 64(1):107186. PubMed ID: 38688353
    [Abstract] [Full Text] [Related]

  • 3. Treatment options for K. pneumoniae, P. aeruginosa and A. baumannii co-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline: an approach based on the mechanisms of resistance to carbapenems.
    Karakonstantis S, Kritsotakis EI, Gikas A.
    Infection; 2020 Dec; 48(6):835-851. PubMed ID: 32875545
    [Abstract] [Full Text] [Related]

  • 4. Multidrug-resistant Gram-negative infections: what are the treatment options?
    Giamarellou H, Poulakou G.
    Drugs; 2009 Oct 01; 69(14):1879-901. PubMed ID: 19747006
    [Abstract] [Full Text] [Related]

  • 5. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG, Golden AR, Zelenitsky S, Wiebe K, Lawrence CK, Adam HJ, Idowu T, Domalaon R, Schweizer F, Zhanel MA, Lagacé-Wiens PRS, Walkty AJ, Noreddin A, Lynch Iii JP, Karlowsky JA.
    Drugs; 2019 Feb 01; 79(3):271-289. PubMed ID: 30712199
    [Abstract] [Full Text] [Related]

  • 6. Management of ventilator-associated pneumonia (VAP) caused by resistant gram-negative bacteria: which is the best strategy to treat?
    Sarda C, Fazal F, Rello J.
    Expert Rev Respir Med; 2019 Aug 01; 13(8):787-798. PubMed ID: 31210549
    [Abstract] [Full Text] [Related]

  • 7. Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria.
    Pontikis K, Karaiskos I, Bastani S, Dimopoulos G, Kalogirou M, Katsiari M, Oikonomou A, Poulakou G, Roilides E, Giamarellou H.
    Int J Antimicrob Agents; 2014 Jan 01; 43(1):52-9. PubMed ID: 24183799
    [Abstract] [Full Text] [Related]

  • 8. New antibiotics and antimicrobial combination therapy for the treatment of gram-negative bacterial infections.
    Bassetti M, Righi E.
    Curr Opin Crit Care; 2015 Oct 01; 21(5):402-11. PubMed ID: 26263298
    [Abstract] [Full Text] [Related]

  • 9. New perspectives in the antibiotic treatment of mechanically ventilated patients with infections from Gram-negatives.
    Karvouniaris M, Pontikis K, Nitsotolis T, Poulakou G.
    Expert Rev Anti Infect Ther; 2021 Jul 01; 19(7):825-844. PubMed ID: 33270485
    [Abstract] [Full Text] [Related]

  • 10. Carbapenem and multidrug resistance in Gram-negative bacteria in a single centre in Italy: considerations on in vitro assay of active drugs.
    Mezzatesta ML, Caio C, Gona F, Cormaci R, Salerno I, Zingali T, Denaro C, Gennaro M, Quattrone C, Stefani S.
    Int J Antimicrob Agents; 2014 Aug 01; 44(2):112-6. PubMed ID: 25059444
    [Abstract] [Full Text] [Related]

  • 11. Colistin: still a lifesaver for the 21st century?
    Karaiskos I, Souli M, Galani I, Giamarellou H.
    Expert Opin Drug Metab Toxicol; 2017 Jan 01; 13(1):59-71. PubMed ID: 27573251
    [Abstract] [Full Text] [Related]

  • 12. Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms.
    Sharma R, Park TE, Moy S.
    Clin Ther; 2016 Mar 01; 38(3):431-44. PubMed ID: 26948862
    [Abstract] [Full Text] [Related]

  • 13. Antimicrobial-resistant Pseudomonas aeruginosa and Acinetobacter baumannii From Patients With Hospital-acquired or Ventilator-associated Pneumonia in Vietnam.
    Biedenbach DJ, Giao PT, Hung Van P, Su Minh Tuyet N, Thi Thanh Nga T, Phuong DM, Vu Trung N, Badal RE.
    Clin Ther; 2016 Sep 01; 38(9):2098-105. PubMed ID: 27612610
    [Abstract] [Full Text] [Related]

  • 14. Clinical data from studies involving novel antibiotics to treat multidrug-resistant Gram-negative bacterial infections.
    Kanj SS, Bassetti M, Kiratisin P, Rodrigues C, Villegas MV, Yu Y, van Duin D.
    Int J Antimicrob Agents; 2022 Sep 01; 60(3):106633. PubMed ID: 35787918
    [Abstract] [Full Text] [Related]

  • 15. Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals.
    Falagas ME, Skalidis T, Vardakas KZ, Legakis NJ, Hellenic Cefiderocol Study Group.
    J Antimicrob Chemother; 2017 Jun 01; 72(6):1704-1708. PubMed ID: 28369471
    [Abstract] [Full Text] [Related]

  • 16. Prophylactic application of antibiotics selects extended-spectrum β-lactamase and carbapenemases producing Gram-negative bacteria in the oral cavity.
    Bratić V, Mihaljević S, Verzak Ž, Pleško E, Lukić A, Ćaćić M, Bedenić B.
    Lett Appl Microbiol; 2021 Aug 01; 73(2):206-219. PubMed ID: 33896011
    [Abstract] [Full Text] [Related]

  • 17. Prevalence and 30-day all-cause mortality of carbapenem-and colistin-resistant bacteraemia caused by Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae: Description of a decade-long trend.
    Balkhair A, Al-Muharrmi Z, Al'Adawi B, Al Busaidi I, Taher HB, Al-Siyabi T, Al Amin M, Hassan KS.
    Int J Infect Dis; 2019 Aug 01; 85():10-15. PubMed ID: 31100418
    [Abstract] [Full Text] [Related]

  • 18. Comparison of the clinical efficacy between tigecycline plus extended-infusion imipenem and sulbactam plus imipenem against ventilator-associated pneumonia with pneumonic extensively drug-resistant Acinetobacter baumannii bacteremia, and correlation of clinical efficacy with in vitro synergy tests.
    Jean SS, Hsieh TC, Hsu CW, Lee WS, Bai KJ, Lam C.
    J Microbiol Immunol Infect; 2016 Dec 01; 49(6):924-933. PubMed ID: 26341302
    [Abstract] [Full Text] [Related]

  • 19. New Drugs for Multidrug-Resistant Gram-Negative Organisms: Time for Stewardship.
    Jean SS, Gould IM, Lee WS, Hsueh PR, International Society of Antimicrobial Chemotherapy (ISAC).
    Drugs; 2019 May 01; 79(7):705-714. PubMed ID: 30972660
    [Abstract] [Full Text] [Related]

  • 20. Antimicrobial Activity of Ceftazidime-Avibactam against Gram-Negative Bacteria Isolated from Patients Hospitalized with Pneumonia in U.S. Medical Centers, 2011 to 2015.
    Sader HS, Castanheira M, Flamm RK.
    Antimicrob Agents Chemother; 2017 Apr 01; 61(4):. PubMed ID: 28069649
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.